Interference No. 103,605
1. A polypeptide having human tumor necrosis factor
activity and being selected from the group consisting of
(a) the polypeptide having the amino acid sequence of the
following formula, and
(b) a polypeptide having an amino acid sequence resulting from
the addition of one or two amino acid residues from the precursor
portion of said polypeptide (a) to the N-terminus of the
following formula:
Ser Ser Ser Arg
Thr Pro Ser Asp Lys Pro Val Ala His Val
Val Ala Asn Pro Gln Ala Glu Gly Gln Leu
Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu
Leu Ala Asn Gly Val Glu Leu Arg Asp Asn
Gln Leu Val Val Pro Ser Glu Gly Leu Tyr
Leu Ile Tyr Ser Gln Val Leu Phe Lys Gly
Gln Gly Cys Pro Ser Thr His Val Leu Leu
Thr His Thr Ile Ser Arg Ile Ala Val Ser
Tyr Gln Thr Lys Val Asn Leu Leu Ser Ala
Ile Lys Ser Pro Cys Gln Arg Glu Thr Pro
Glu Gly Ala Glu Ala Lys Pro Trp Tyr Glu
Pro Ile Tyr Leu Gly Gly Val Phe Gln Leu
Glu Lys Gly Asp Arg Leu Ser Ala Glu Ile
Asn Arg Pro Asp Tyr Leu Asp Phe Ala Glu
Ser Gly Gln Val Tyr Phe Gly Ile Ile Ala
Leu.
(underlining added for emphasis)
Significantly, Yamada acknowledges (YB-3) that if it is
found that Yamada’s three Japanese priority applications9 do not
provide a sufficient written description of the subject matter of
claims 1 and 4, then “the Pennica et al. and Aggarwal et al.
8(...continued)
be identical to Yamada claim 1.
9 The three Yamada Japanese priority applications are 43,617/84
(AX-7); 82,653/84 (AX-8); and 172,307/84 (AX-9). These three
applications will be respectively referred to hereinafter as J1,
J2 and J3.
6
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007